Daré Bioscience ( (DARE) ) has released its Q3 earnings. Here is a breakdown of the information Daré Bioscience presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Daré Bioscience is a health biotech company focused on advancing women’s health solutions through innovative science and real-world applications, operating primarily in the women’s health sector.
In its latest earnings report, Daré Bioscience highlighted its strategic advancements and financial results for the third quarter of 2025. The company is preparing to launch its DARE to PLAY™ Sildenafil Cream by year-end, marking a significant step towards revenue generation.
Key financial metrics revealed a cash position of $23.1 million as of September 30, 2025, with a decrease in R&D expenses compared to the previous year due to increased non-dilutive funding. The company reported a net loss of $3.56 million for the quarter, an improvement from the $4.70 million loss in the same period last year. Strategic announcements included positive interim results for the Ovaprene® Phase 3 study and progress in grant-funded programs targeting HPV and non-hormonal contraception.
Looking forward, Daré Bioscience is poised to introduce four women’s health products over the next two years, with continued efforts to secure FDA approval for its innovative solutions. The company’s management remains optimistic about its potential to impact women’s health and deliver value to shareholders.